UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Bladder ultrasonography for diagnosing detrusor overactivity: test accuracy study and economic evaluation

Health technology assessment (Winchester, England), 2016-01, Vol.20 (7), p.1-150

2016

Volltextzugriff (PDF)

Asymmetric synthesis of ( R)-(−)-chlozolinate through a chemoenzymatic procedure

Tetrahedron: asymmetry, 2001-02, Vol.12 (2), p.271-277

2001

Volltextzugriff (PDF)

Systematic tissue-specific functional annotation of the human genome highlights immune-related DNA elements for late-onset Alzheimer's disease

PLoS genetics, 2017-07, Vol.13 (7), p.e1006933-e1006933

2017

Volltextzugriff (PDF)

A Powerful Approach to Estimating Annotation-Stratified Genetic Covariance via GWAS Summary Statistics

American journal of human genetics, 2017-12, Vol.101 (6), p.939-964

2017

Volltextzugriff (PDF)

Effects of bowel preparation on intestinal bacterial associated urine and faecal metabolites and the associated faecal microbiome

BMC gastroenterology, 2022-05, Vol.22 (1), p.240-9, Article 240

2022

Volltextzugriff (PDF)

Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial

Nature medicine, 2020-11, Vol.26 (11), p.1733-1741

2020

Volltextzugriff (PDF)

Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions

European urology, 2019-01, Vol.75 (1), p.100-110

2019

Volltextzugriff (PDF)

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial

ESMO open, 2020-11, Vol.5 (6), p.e001079-e001079, Article e001079

2020

Volltextzugriff (PDF)

Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma

British journal of cancer, 2018-05, Vol.118 (9), p.1176-1178

2018

Volltextzugriff (PDF)

Adjuvant Vascular Endothelial Growth Factor–targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis

European urology, 2018-11, Vol.74 (5), p.611-620

2018

Volltextzugriff (PDF)

EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort † : Under the Auspices of the EAU-ESMO Guidelines Committees

European urology, 2020-02, Vol.77 (2), p.223

2020

Volltextzugriff (PDF)

Atomically resolved tomography to directly inform simulations for structure–property relationships

Nature communications, 2014-11, Vol.5 (1), p.5501-5501, Article 5501

2014

Volltextzugriff (PDF)

Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma

British journal of cancer, 2018-09, Vol.119 (6), p.663-669

2018

Volltextzugriff (PDF)

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

The lancet oncology, 2019-10, Vol.20 (10), p.1370-1385

2019

Volltextzugriff (PDF)

Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial

The lancet oncology, 2022-07, Vol.23 (7), p.888-898

2022

Volltextzugriff (PDF)

Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

The lancet oncology, 2018-01, Vol.19 (1), p.27-39

2018

Volltextzugriff (PDF)

Clarification needed for pembrolizumab as adjuvant therapy in clear cell renal cell carcinoma – Authors' reply

The lancet oncology, 2023-01, Vol.24 (1), p.e1-e2

2023

Volltextzugriff (PDF)

Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma

Journal for immunotherapy of cancer, 2022-03, Vol.10 (3), p.e004316

2022

Volltextzugriff (PDF)

Landscape of subsequent therapies in perioperative immunotherapy trials across multiple cancer types

The lancet oncology, 2024-11

2024

Volltextzugriff (PDF)

Ecological Fitness of a Multiple Herbicide-Resistant Lolium rigidum Population: Dynamics of Seed Germination and Seedling Emergence of Resistant and Susceptible Phenotypes

The Journal of applied ecology, 2005-04, Vol.42 (2), p.288-298

2005

Volltextzugriff (PDF)

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

The lancet oncology, 2022-09, Vol.23 (9), p.1133-1144

2022

Volltextzugriff (PDF)

1 – 25 von 320

Suche als RSS-Feed

Aktive Filter

KollektionJournals@Ovid Complete

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(265)
Mit Volltextzugriff
(289)

Publikationsform

Artikel
(317)
Bücher
(3)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(187)
Life Sciences & Biomedicine
(151)
Humans
(105)
Oncology
(75)
Female
(52)
Biological And Medical Sciences
(44)
Adult
(37)
Male
(36)
Physical Sciences
(36)
Middle Aged
(35)
Medical Sciences
(32)
Aged
(28)
Chemistry
(28)
Renal Cell Carcinoma
(25)
Physics
(23)
Carcinoma, Renal Cell - Drug Therapy
(22)
Kidney Neoplasms - Drug Therapy
(20)
Animals
(19)
Pharmacology. Drug Treatments
(19)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(18)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(4)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Bladder ultrasonography for diagnosing detrusor overactivity: test accuracy study and economic evaluation

Asymmetric synthesis of ( R)-(−)-chlozolinate through a chemoenzymatic procedure

Systematic tissue-specific functional annotation of the human genome highlights immune-related DNA elements for late-onset Alzheimer's disease

A Powerful Approach to Estimating Annotation-Stratified Genetic Covariance via GWAS Summary Statistics

Effects of bowel preparation on intestinal bacterial associated urine and faecal metabolites and the associated faecal microbiome

Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial

Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions

Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial

Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma

Adjuvant Vascular Endothelial Growth Factor–targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis

EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort † : Under the Auspices of the EAU-ESMO Guidelines Committees

Atomically resolved tomography to directly inform simulations for structure–property relationships

Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma

Clarification needed for pembrolizumab as adjuvant therapy in clear cell renal cell carcinoma – Authors' reply

Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma

Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial

Landscape of subsequent therapies in perioperative immunotherapy trials across multiple cancer types

Ecological Fitness of a Multiple Herbicide-Resistant Lolium rigidum Population: Dynamics of Seed Germination and Seedling Emergence of Resistant and Susceptible Phenotypes

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Aktive Filter

Suchergebnisse filtern